Navigation Links
NKTR in Medical News

Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis

...ed in Cimzia(R) Through Exclusive Nektar-UCB Collaboration SAN FRANCISCO, Calif., May 14 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) confirmed today UCB's announcement that the US Food and Drug Administration (FDA) has approved Cimzia(R) (certolizumab pegol), the only PEGylated an...

Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston

... SAN CARLOS, Calif., May 12 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) is scheduled to present at the upcoming Deutsche Bank 34th Annual Health Care Conference in Boston at the Boston InterContinental Hotel on Monday, M...

Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets

... SAN CARLOS, Calif., April 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) will announce its financial results for the first quarter ended March 31, 2009 on Wednesday, May 6, 2009, after the close of U.S.-based financial ma...

NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR

... DENVER and SAN CARLOS, Calif., April 22 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) presented data today at the American Association for Cancer Research (AACR) 100th Annual Meeting demonstrating that NKTR-105, a novel PEGylated form...

Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors

... SAN CARLOS, Calif., Feb. 17 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced today that the first patients have been dosed in a Phase 1 dose-escalation study of NKTR-105, a novel PEGylated form of docetaxel. The Ph...

Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results

... SAN CARLOS, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today announced that it has repurchased 32%, or $100.0 million, of its outstanding convertible debt for approximately 48 cents on the dollar, for a ...

Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets

... SAN CARLOS, Calif., Oct 23 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) will announce its financial results for the third quarter ended September 30, 2008 on Thursday, November 6, 2008, after the close of U.S.-based fina...

Nektar Therapeutics Announces Second Quarter 2008 Results

... SAN CARLOS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today announced the company's financial results for the second quarter and six-months ended June 30, 2008. Cash, cash equivalents, and short-term ...

Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer

... SAN CARLOS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today announced the appointment of Randall Moreadith, M.D., Ph.D., to the position of Senior Vice President of Drug Development and Chief Developmen...

Nektar Therapeutics Announces First Quarter 2008 Results

... SAN CARLOS, Calif., May 7 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced today the company's financial results for the first quarter ended March 31, 2008. Cash, cash equivalents, and short-term investments wer...
NKTR in Medical Technology

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

... SAN CARLOS, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today reported its financial results for the second quarter ended June 30, 2009. Net loss for the quarter ended June 30, 2009 was $32.1 mill...

Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)

...s Achieved at Two Dose Levels with No Reversal of Analgesia SAN CARLOS, Calif., March 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced positive topline results today from a Phase 2 double-blind, randomized, placebo-controlled study of NKTR-118 in patients with opioid-induc...

Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)

...in Advanced Breast and Ovarian Cancers SAN CARLOS, Calif., June 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today announced an expanded Phase 2 development plan for NKTR-102 (PEG-irinotecan). The company will target newly-characterized colorectal cancer pa...

Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)

... SAN CARLOS, Calif., May 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) will host a meeting and Webcast on Monday, June 2, 2008 at 6:30 PM Central Time to discuss the company's lead oncology program, NKTR-102 (PEG-irinot...

Amikacin Inhale Shows Promising Results in Phase II Study

... mechanically-ventilated patients TORONTO and BERLIN, May 19 /PRNewswire-FirstCall/ -- Bayer HealthCare together with Nektar Therapeutics (Nasdaq: nktr ), today presented positive preliminary Phase II data on their unique drug-device combination Amikacin Inhale at the American Thoracic Society (ATS) a...

Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings

...Molecule with Demonstrated Therapeutic Activity SAN CARLOS, Calif., May 16 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced initial results today from a Phase 1 study of NKTR- 102, PEGylated irinotecan. The data shows significant anti-tumor activity in patients ...

NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting

...f., May 7 /PRNewswire-FirstCall/ -- New Phase 1 clinical trial results for NKTR-118 (oral PEG-naloxol) were presented by Nektar Therapeutics (Nasdaq: nktr ) this week at the Annual Meeting of the American Pain Society (APS) in Tampa, Florida. In this multiple-dose Phase 1 study, oral NKTR-118 was shown t...

Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting

... SAN FRANCISCO, April 14 /PRNewswire-FirstCall/ -- Positive preclinical data was presented by Nektar Therapeutics (Nasdaq: nktr ) this week for its lead oncolytic candidate, NKTR-102 (PEG-irinotecan), which demonstrated enhanced anti-tumor activity in a mouse xenograft model of...

Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings

... SAN FRANCISCO, April 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced today that positive preclinical and clinical results for its pipeline programs will be presented at numerous medical and scientific meetin...

Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients

... SAN CARLOS, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced today that it has ceased all negotiations with potential partners for its inhaled insulin programs as a result of new data analysis from o...
NKTR in Biological Technology

Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City

... SAN CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) is scheduled to present at the upcoming BMO Capital Markets 9th Annual Focus on Healthcare Conference at the Millennium Broadway Hotel in New York...

Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets

... SAN CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) will announce its financial results for the second quarter ended June 30, 2009 on Tuesday, August 4, 2009, after the close of U.S.-based financial m...

Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer

... SAN CARLOS, Calif., June 9 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today announced the promotion of Lorianne Masuoka, M.D. to the position of Chief Medical Officer. Dr. Masuoka reports to Nektar's Senior Vice Presi...

Nektar Therapeutics Reports First Quarter 2009 Financial Results

... SAN CARLOS, Calif., May 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today reported its financial results for the first quarter ended March 31, 2009. Net loss for the quarter ended March 31, 2009 was $31.8 milli...

Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston

... SAN CARLOS, Calif., March 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: nktr ) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming Cowen and Company 29th Annual Healthcare Conference ...

Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results

... SAN CARLOS, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) today reported its financial results for the fourth quarter and year ended December 31, 2008. "2008 was a transformational year for Nektar," ...

Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets

... SAN CARLOS, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) will announce its financial results for the fourth quarter and year ended December 31, 2008 on Wednesday, February 25, 2009, after the close of U.S....

Nektar Announces Retirement of Irwin Lerner from Board of Directors

... SAN CARLOS, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced today that Irwin Lerner has retired from its Board of Directors effective January 23, 2009. Mr. Lerner, former Chairman of Hoffmann-La Ro...

First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer

... SAN CARLOS, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: nktr ) announced today that dosing has started in a Phase 2 clinical trial of NKTR-102 in platinum-resistant ovarian cancer. Regulatory approvals have als...

Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco

... SAN CARLOS, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Nektar Therapeutics' (Nasdaq: nktr ) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 27th Annual J.P. Morgan Healthcare Conference in San...
Other Tags
(Date:11/18/2014)... HealthDay Reporter MONDAY, Nov. 17, ... to extremely low levels with a combination drug appears ... patients with clogged arteries, a new study found. ... Vytorin, a drug that combines a cholesterol-lowering statin called ... investigator Dr. Christopher Cannon, a cardiologist at Brigham and ...
(Date:11/18/2014)... News) -- Women who started smoking at a young ... menstrual pain, a new study suggests. About 29 ... has been suspected as a risk factor for severe ... of the new study said. The researchers analyzed ... study of women,s health in Australia. About 14 percent ...
(Date:11/18/2014)... Hills, CA (PRWEB) November 18, 2014 ... and workflow solutions, announced today their Gold sponsorship of ... November 19th through Friday, November 21st at the Fargo, ... event offering targeted Microsoft Dynamics GP training sessions and ... the Microsoft campus is an excellent way for users ...
(Date:11/18/2014)... Recently, Wigsbuy has introduced its newest collection of ... greatly discounted prices now, up to 85% off. , Wigsbuy ... products, offering many real and synthetic hair products. In order ... uses high quality materials to make its hair wigs, which ... , “We are offering a full line of human ...
(Date:11/18/2014)... Thompson HealthDay Reporter , MONDAY, ... patients can safely take aspirin combined with a blood-thinning medication, ... a patient,s risk of early death, according to a new ... Heart Association in Chicago. The report was also published online ... data from more than a dozen clinical trials revealed no ...
Breaking Medicine News(10 mins):Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Altec Joins the 2014 Great Plains User Conference (GPUC) as a Gold Sponsor, Demonstrating the Capabilities of Certified for Microsoft Dynamics Product doc-link 2Health News:Altec Joins the 2014 Great Plains User Conference (GPUC) as a Gold Sponsor, Demonstrating the Capabilities of Certified for Microsoft Dynamics Product doc-link 3Health News:It Is The Most Wonderful Time To Buy Full Lace Wigs At Wigsbuy.com 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 3
(Date:11/11/2014)... Inc., a Chicago -based digital forensics ... of Yaniv Schiff from Senior Computer Forensics ... role as Director, he will lead company efforts to ... provide leadership within the company,s digital forensics practice area.  ... Schiff joined Forensicon in 2006 and has ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
(Date:11/7/2014)... CORAL SPRINGS, Florida , November 6, 2014 ... improved secure authentication for better mobile security revolutionizing online transactions. ... NXTD ), Alibaba Holdings Ltd. (NYSE: BABA ), ... MSFT ), eBay Inc. (NASDAQ: EBAY ... (NASDAQ: NXTD and NXTDW), a biometric authentication ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
Other Contents